Skip to content

Journal · Hematology · Updated 19 November 2026

Leukemia

Read Leukemia articles on DeepDyve. No university library needed.

Leukemia has published since 1987 and covers leukemia and other blood cancers, from their genetics and biology to clinical trials of new treatments. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Leukemia
November 2026 issue

Leukemia at a glance

Full title
Leukemia
Abbreviation (NLM)
Leukemia
Publisher
Springer Nature
Print ISSN
0887-6924
Online ISSN (eISSN)
1476-5551
First published
1987
Subjects
Hematology, Neoplasms
Access model
Hybrid (63% free to read in 2026)

Ways to access Leukemia

63% of the articles Leukemia published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 63% of Leukemia articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  3. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  4. A library. Your university, hospital or public library may subscribe to Leukemia. Check its journal list and whether it offers remote access.
  5. DeepDyve. Read Leukemia articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Recent Leukemia research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. Open accessAcute myeloid leukemia · Genetics

    Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study

    Hernández-Sánchez and colleagues report a HARMONY risk classification for adult NPM1-mutated acute myeloid leukemia, based on co-mutations in FLT3-ITD, DNMT3A, IDH1/IDH2 and TET2, that reclassified 42.7% of patients in the training cohort into a different European LeukemiaNet 2022 risk category.

    Hernández-Sánchez et al. · Leukemia, published online January 14, 2026 · DOI 10.1038/s41375-025-02851-9

  2. Open accessMultiple myeloma · Immunotherapy

    Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study

    In a phase 1 study of 95 patients with relapsed or refractory multiple myeloma given subcutaneous alnuctamab, Bar and colleagues report an overall response rate of 58.9%, and 71.4% in the 30-mg cohort, with cytokine release syndrome in 57.9%, none grade 3 or 4.

    Bar et al. · Leukemia, published online January 7, 2026 · DOI 10.1038/s41375-025-02841-x

  3. LitStreamChronic lymphocytic leukemia · Trial endpoints

    Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies

    Analyzing 43 trials involving 9628 subjects with chronic lymphocytic leukemia, Wang and colleagues report that detectable measurable residual disease carried a higher individual-level risk of progression or death (HR = 3.67), while the trial-level correlation between MRD results and progression-free survival was weak.

    Wang et al. · Leukemia, published online April 30, 2026 · DOI 10.1038/s41375-026-02970-x

  4. LitStreamAcute myeloid leukemia · Genomics

    NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners

    Using targeted-capture sequencing, Chonabayashi and colleagues report 41 NUP98-rearranged cases among 1569 AML cases, including two novel fusions (NUP98::MEOX2 and NUP98::HOXA6), and say NUP98-rearranged AML showed higher relapse rates and shorter event-free survival.

    Chonabayashi et al. · Leukemia, published online January 7, 2026 · DOI 10.1038/s41375-025-02848-4

  5. LitStreamAcute myeloid leukemia · Measurable residual disease

    Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia

    In 656 adults with core binding factor AML from the retrospective RetroCBF study and the prospective CBF-2006 trial, Vasseur and colleagues report that KIT-TKD mutations in RUNX1::RUNX1T1 and FLT3-ITD in CBFB::MYH11 were associated with higher relapse risk after accounting for measurable residual disease.

    Vasseur et al. · Leukemia, published online March 26, 2026 · DOI 10.1038/s41375-026-02900-x

See every Leukemia article on DeepDyve

Questions about Leukemia

How can I read Leukemia articles without a subscription?

63% of Leukemia articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Leukemia articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Leukemia?

Leukemia isn’t abbreviated: its NLM (PubMed) abbreviation is simply Leukemia.

What is the ISSN of Leukemia?

The print ISSN is 0887-6924 and the online ISSN is 1476-5551.

Is Leukemia open access?

Leukemia is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 19, 2026, 215 of 340 Leukemia articles (63%) carry a Creative Commons license, per Crossref.

Leukemia articles on DeepDyve are licensed from Springer Nature. Journal facts as of 19 November 2026.

Start reading Leukemia today

One month free, then less than $2 a day. Leukemia, plus millions of articles from thousands of journals.

Start free month

Like this: